Biolyst › SVASINOVAC BIOTECH LTD is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.
The next scheduled catalyst is Phase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccine in Children Aged 2-6 Years on November 15, 2026. There are 10 upcoming events on record.
Cash runway is approximately 139.9 months based on the most recent reported cash position and quarterly operating burn as of 2025-12-31.
Across 66 concluded trials, 98% reached completion rather than being terminated or withdrawn.
Upcoming catalysts
Date Event Type Phase
November 15, 2026
Phase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccine in Children Aged 2-6 Years Trial Milestone
Phase 3
December 30, 2026
Immunogenicity and Safety of Rabies Vaccine (Serum-free Vero Cell) in a Pre-exposure Prophylaxis Regimen Trial Milestone
Phase 3
January 15, 2027
Phase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccine in Children Aged 12-23 Months Trial Milestone
Phase 3
January 30, 2027
Immunogenicity and Safety of Rabies Vaccine (Serum-free Vero Cell) in a Simulated Post-exposure Prophylaxis Regimen Trial Milestone
Phase 3
February 15, 2027
A Phase IV Clinical Trial of Influenza Vaccine (Split Virion), Inactivatedin (Anflu®) Pregnant Women (AnFLU-PREG) Trial Milestone
Phase 4
April 15, 2027
Phase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccine in Children Aged 3-5 Months Trial Milestone
Phase 3
April 15, 2027
Phase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccine in Children Aged 6-11 Months Trial Milestone
Phase 3
September 15, 2027
Phase Ⅲ Clinical Trial of an Inactivated Hepatitis A Vaccine Trial Milestone
Phase 3
December 15, 2027
Protective Efficacy , Immunogenicity and Safety of the Tetravalent Inactivated Enterovirus Vaccine (Vero Cell). Trial Milestone
Phase 3
March 17, 2028
Immunogenicity and Safety of Hepatitis A Among People Aged 18-50 Years Old Trial Milestone
Phase 4
Track SVA alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open SVA in the tracker
Recent history
Date Event Type Phase
September 30, 2026
Phase IIIb Clinical Trial to Evaluate Lot-to-lot Consistency of Sinovac Rabies Vaccine Trial Milestone
Phase 3
September 8, 2026
Phase IV Clinical Study of Sequential Vaccination of Sabin Strain and Wild Strain Inactivated Poliovirus Vaccine Trial Milestone
Phase 4
August 17, 2026
6-K filed: Foreign issuer report Filing
—
July 15, 2026
6-K filed: Foreign issuer report Filing
—
June 30, 2026
Study to Evaluate the Safety of a Lyophilized RSV mRNA Vaccine Trial Milestone
Phase 1
June 15, 2026
6-K filed: Foreign issuer report Filing
—
June 5, 2026
Results filed (20-F) Earnings
—
June 5, 2026
6-K filed: Foreign issuer report Filing
—
May 31, 2026
Study to Evaluate the Safety and Immunogenicity of a Lyophilized Herpes Zoster Virus mRNA Vaccine Trial Milestone
Phase 1/Phase 2
May 29, 2026
6-K filed: Foreign issuer report Filing
—
May 21, 2026
6-K filed: Foreign issuer report Filing
—
May 8, 2026
6-K filed: Foreign issuer report Filing
—
May 7, 2026
6-K filed: Foreign issuer report Filing
—
April 30, 2026
Results filed (20-F) Earnings
—
April 11, 2026
Phase IV Clinical Study of sIPV Administration in Adolescent and Adult Populations Trial Milestone
Phase 4
March 15, 2026
Influenza Vaccine (Split Virion), Inactivated, Quadrivalent in Pregnant Women Trial Milestone
Phase 3
January 22, 2026
6-K filed: Foreign issuer report Filing
—
January 15, 2026
Immunogenicity and Safety of Different Dosages of Rabies Vaccine (Serum-free Vero Cell) Trial Milestone
Phase 2
January 5, 2026
6-K filed: Foreign issuer report Filing
—
December 30, 2025
Tolerability, Safety, and Immunogenicity of Tetravalent Inactivated Enterovirus Vaccine (Vero Cell). Trial Milestone
Phase 1/Phase 2
December 19, 2025
Inactivated Bivalent Enterovirus Vaccine (Vero Cell) Phase I/II Clinical Trial Trial Milestone
Phase 1/Phase 2
December 17, 2025
6-K filed: Foreign issuer report Filing
—
November 30, 2025
Efficacy, Safety, and Immunogenicity of the Bivalent Inactivated Enterovirus Vaccine (Vero Cell) Trial Milestone
Phase 3
November 20, 2025
6-K filed: Foreign issuer report Filing
—
November 5, 2025
6-K filed: Foreign issuer report Filing
—
September 18, 2025
Phase I Clinical Trial of Influenza Vaccine (Split Virion), Inactivated (High Dose) Trial Milestone
Phase 1
September 10, 2025
Booster Dose of sIPV Co-administered With MMR and HepA-I. Trial Milestone
Phase 4
August 21, 2025
6-K filed: Foreign issuer report Filing
—
July 11, 2025
6-K filed: Foreign issuer report Filing
—
July 10, 2025
6-K filed: Foreign issuer report Filing
—
About this data
Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.